The TEPI Patch, based on a proprietary adhesive developed by its scientists, has a high drug loading capacity, enabling patients to take medicines in higher concentrations with faster release rates and without the complications associated with oral drugs. Medherant also undertakes feasibility studies for other companies to investigate whether their drugs can be formulated for transdermal delivery using the TEPI technology, and welcomes enquiries from companies interested in licensing its products for commercialisation or undertaking feasibility studies.